Article
Envision Pharma Group
Is it Ever Too Early or Too Late
Summary
In this episode, Tom Caravela is joined by Jeff Vaughn and Dean McAllister to discuss the critical timing of Medical Science Liaison (MSL) involvement in drug development. They explore misconceptions and historical approaches, highlighting the impact and internal value of early MSL engagement. The conversation addresses challenges MSLs face, the adaptation to virtual engagement, and the importance of strategic prioritization within a global framework. They delve into the integration of AI and long-term clinical trial planning, emphasizing the need to bridge theory and practice. The episode concludes with insights on networking among industry leaders and sponsor appreciation.
Key Points
- Involving MSLs and subject matter experts early in the drug development process can significantly enhance trial design, patient recruitment, and overall clinical strategy.
- MSLs provide critical insights and establish valuable relationships with KOLs and HCPs, which can accelerate trial accrual and improve the quality of the clinical data collected.
- A strategic framework for involving MSLs should include scalable deployment, prioritization of key territories, and a consistent global approach to ensure alignment and maximize impact throughout the product lifecycle.
Medical Science Liaison, drug development, early MSL engagement, clinical trial planning, strategic prioritization
Related Topics
You May Also Like
Envision Pharma Group
Press Release
Joe Pardavila sits down with Dr. Ramin Farhood and Dr. Kirk Shepard
Breaking Silos in Oncology Dr Ramin Farhood & Dr Kirk Shepard on Voices of Oncology
Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Social Media Listening Evolved
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD